Loading organizations...
Haptena Therapeutics, based in Turin, Italy, develops targeted immunotherapies for oncogene-driven cancers, with a primary focus on KRAS-mutant tumors affecting lung, pancreatic, and colorectal cancers. The company aims to advance precision oncology by addressing tumor resistance mechanisms and immune interactions, specifically to improve treatment durability and overcome limitations of existing therapies. It recently secured €3 million in seed financing from lead investor Claris Ventures to advance its discovery platform and initial programs. Pietro Puglisi, Managing Partner at Claris Ventures, played a key role in the investment for the seed-stage biotech. The organization was founded in 2025 by Professors Chiara Ambrogio of the University of Turin and Roberto Chiarle, who also holds positions at Boston Children’s Hospital and Harvard Medical School.
Haptena Therapeutics has raised $3.5M across 1 funding round.
Haptena Therapeutics has raised $3.5M in total across 1 funding round.
Haptena Therapeutics has raised $3.5M across 1 funding round. Most recently, it raised $3.5M Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2025 | $3.5M Seed | Pietro Puglisi | — | Announced |
Haptena Therapeutics has raised $3.5M in total across 1 funding round.
Haptena Therapeutics's investors include Pietro Puglisi.